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ABSTRACT
Objective: To evaluate the effect of adalimumab on the
frequency of anterior uveitis (AU) flares in patients with
active ankylosing spondylitis (AS).
Methods: We determined the history of ophthalmologist-
diagnosed AU in 1250 patients with active AS who were
enrolled in a multinational, open-label, uncontrolled clinical
study of treatment with adalimumab, 40 mg every other
week for up to 20 weeks. All AU flares were documented
throughout the adalimumab treatment period plus
70 days. We compared the rates of AU flares per
100 patient years (PYs) reported during the year before
adalimumab treatment with rates during adalimumab
treatment, in total and by patient subgroups.
Results: The AU flare rates before adalimumab treatment
were 15/100 PYs in all patients (n=1250), 68.4/100 PYs
in 274 patients with a history of AU flares, 176.9/100 PYs
in 106 patients with a recent history of AU flares, 192.9/
100 PYs in 28 patients with symptomatic AU at baseline
and 129.1/100 PYs in 43 patients with a history of chronic
uveitis. During adalimumab treatment, the rate of AU
flares was reduced by 51% in all patients, by 58% in 274
patients with a history of AU, by 68% in 106 patients with
a recent history of AU, by 50% in 28 patients with
symptomatic AU at baseline and by 45% in 43 patients
with chronic uveitis. AU flares during adalimumab
treatment were predominantly mild. Two patients with
periods of high AS disease activity had new-onset AU
during the treatment period.
Conclusions: Results of this prospective open-label
study suggest that adalimumab had a substantial
preventive effect on AU flares in patients with active AS,
including patients with a recent history of AU flares.
Clinical trials: ClinicalTrials.gov Identifier: NCT00478660.
Tumour necrosis factor (TNF) antagonists are
highly effective agents for the treatment of
patients with active ankylosing spondylitis (AS).
In addition to the spine, the immunological
inflammation of AS may also involve peripheral
joints and extraskeletal structures, such as the eye,
skin and bowel. Between 20% and 40% of patients
with AS experience at least one flare of anterior
uveitis (AU) at any time during the course of the
disease.
12An attack of AU may even be the first
symptom that leads to the diagnosis of AS.
34
Underlying AS is diagnosed in up to 50% of
patients with AU, particularly in the presence of
the human leukocyte antigen (HLA)-B27.
5 The
course of AU varies widely; patients may experi-
ence only one uveitis flare in a lifetime, whereas
others have recurrent episodes. Some patients also
have chronic uveitis that is characterised by
persistent episodes of uveitis (defined as at least
3 months in duration) with a symptom-free
interval of less than 3 months after treatment
discontinuation.
6
Among the traditional disease-modifying anti-
rheumatic drugs (DMARDs) that are generally of
dubious effect in patients with AS compared with
patients with rheumatoid arthritis or with psor-
iatic arthritis, a preventive effect of DMARDs on
AU flares has been reported only for sulfasalazine.
7
Acute or chronic episodes of AU, particularly in
children with juvenile inflammatory arthritis and
uveitis, have been successfully treated with inflix-
imab, whereas etanercept was mostly ineffec-
tive.
18 – 1 6The effect of TNF antagonists on AU in
patients with spondyloarthritis (SpA) or AS was
analysed in one large retrospective study and one
meta-analysis of seven clinical trials, four of which
were placebo-controlled, randomised trials.
17 18 The
retrospective study suggested that the TNF
antagonists infliximab and adalimumab reduced
the rate of AU flares, whereas the frequency of AU
flares in patients with SpA who were treated with
etanercept remained unchanged.
18 In the meta-
analysis, infliximab and etanercept therapies
reduced the incidence of AU flares, and infliximab
appeared to be more effective than etanercept;
adalimumab was not evaluated.
17 By contrast,
new-onset uveitis was reported during TNF-
antagonist therapy in patients with rheumatic
disorders that are not commonly associated with
uveitis. A review of the literature indicates that
new-onset AU has been reported primarily during
etanercept treatment, rarely during infliximab
treatment and not during adalimumab treat-
ment.
11 19–24 Questions of clinical interest include
whether patients with AS and AU respond
similarly to TNF antagonists compared with
patients without a history of AU and whether
there is a correlation between adalimumab effec-
tiveness on AS and on prevention of AU flares.
Here, we report analyses of data from the ‘‘Review
of safety and effectiveness witH Adalimumab in
Patients with active ankylosing SpOnDYlitis’’
(RHAPSODY) trial. With 1250 patients enrolled,
this is the largest prospective clinical trial to
evaluate the effect of adalimumab on AU flares
in patients with AS to date.
PATIENTS AND METHODS
Patients
Adults >18 years of age with active AS according
to the modified New York Criteria for Ankylosing
Spondylitis 1984
25 and with a Bath AS Disease
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26 (BASDAI) >4 despite treatment with at least
one non-steroidal anti-inflammatory drug (NSAID) were
enrolled. Previous treatment with another TNF antagonist
was allowed if the therapy had been discontinued at least
3 weeks (for etanercept) or at least 2 months (for infliximab)
before the first adalimumab injection. Ongoing treatment with
NSAIDs including cyclo-oxygenase 2 inhibitors, glucocorticoids
((10 mg/dl prednisolone equivalent) and/or DMARDs was
allowed. The dosage regimen of current topical therapy with
glucocorticoids or other agents in patients with uveitis could be
tapered during the study.
Study design
This is a prespecified subanalysis of a multinational, prospec-
tive, open-label, uncontrolled clinical study of adalimumab
40 mg every other week for the treatment of patients with AS.
Patients were enrolled at 211 clinical centres in 15 European
countries. This study was approved by an independent ethics
committee at each centre and all patients provided written,
informed consent.
Details of the study design have been published elsewhere
previously.
27 All patients were treated with adalimumab 40 mg
every other week for 12 weeks. Patients with documented AU
flares within 1 year before and/or at baseline continued
receiving adalimumab up to week 20 to provide a longer
observation period. Measures of adalimumab effectiveness were
collected at weeks 2, 6, 12 and 20 (as applicable). At baseline, the
history of ophthalmologist-diagnosed AU was confirmed in the
medical record of each patient, and the AU was assessed as
acute or chronic. Chronic uveitis was defined according to The
Standardization of Uveitis Nomenclature Working Group as
persistent AU flares (ie, >3 months in duration) with relapse
occurring in the previous 3 months.
6 The number of recent AU
flares (in the 12 months before and/or at baseline) were
documented categorically as zero, one to two and three or
more episodes. Any flare of AU that occurred during the
adalimumab treatment period and up to 70 days after the last
adalimumab injection was captured as an adverse event (AE).
In addition, advanced ankylosis at baseline, defined as at least
Stage IV (involvement of >50% of the spine in .2 segments),
was documented by the investigators based on historical
radiographs.
28 The responses of spinal symptoms were evaluated
by the Assessment in Spondyloarthritis International Society
(ASAS) criteria as improvement by at least 20% (ASAS20) and
by at least 40% (ASAS40),
29 30 ASAS 5/6 criteria (improvement
of at least 20% in five of six ASAS criteria), ASAS partial
remission (value of ,2 on a 0–10-point scale in each of the four
ASAS20 domains),
29 30 and improvement by at least 50% in the
BASDAI (BASDAI 50).
26 31 32
Statistical analyses
The methodology for this prespecified analysis of AU flare rates
was described in the clinical trial protocol and statistical
analysis plan before enrolment of the first patient in the study.
The rate of AU flares during the entire adalimumab treatment
period (including the 70-day follow-up period) was calculated as
events/100 patient years (PY) for all patients enrolled in the
study (n=1250), and for 4 subsets of patients. Three subsets
were determined by the timing of AU activity with respect to
the baseline study visit, as follows: patients with a history of
uveitis (ie, at least one AU flare anytime in the course of their
AS), patients with a recent AU flare (ie, at least one flare during
the 12 months before and/or at baseline) and patients with
symptomatic AU at baseline. The fourth subset was based on
the clinical course of AU and included patients with chronic AU.
The rate of AU flares during adalimumab therapy was
compared with the rate of AU flares in the 12 months before
baseline per 100 PYs for all patients and the four subsets of
patients with a Wilcoxon signed rank test. Because the number
of flares in the past 12 months had been categorically
documented (ie, 0, 1 to 2, or 3 or more episodes), the total
number of flares was calculated by multiplying the number of
patients in the 1–2 category by 1.5 (ie, the mean of the 1–2
category), and multiplying the number of patients in the >3
category by 3 (ie, the minimum number of episodes in this
category). The ASAS40 and BASDAI 50 response rates at week
12 were compared in patients with vs without a history of
uveitis, and also in patients without an AU flare vs patients
with at least one AU flare during adalimumab treatment.
RESULTS
Clinical characteristics and AU history
Patients with active AS (n=1250) had a mean disease duration
of 11 years. A history of ophthalmologist-diagnosed AU was
documented in 274 of 1250 (21.9%) enrolled patients. Of the
274 patients with AU, 43 had chronic uveitis; 106 had a recent
history of uveitis and 28 had symptomatic AU at baseline.
The mean/median time of time from diagnosis of AU to
study enrolment was 9.9/7.4 years in the 274 patients with a
history of AU. The demographic and disease characteristics of
all patients and of patients with a history of AU were generally
similar. Sulfasalazine treatment was ongoing in 13% (36/274) of
patients with a history of AU and in 10% (127/1250) of all
patients. The percentages of patients with treatment with a
previous TNF antagonist was 26% (326/1250) of all patients and
23% (63/274) of patients with a history of AU. The percentage
of HLA-B27–positive patients was greater for patients with a
history of AU than among the total study population or
compared with patients without a history of uveitis, of whom
80% were HLA-B27 positive (data not shown). The serum
concentration of C-reactive protein (CRP) was greater in
patients with symptomatic AU at baseline compared with all
other patient groups (table 1).
The majority of patients (84%, 231/274) had experienced
acute AU and 16% (43/274) of patients had developed chronic
uveitis. Among the 106 patients with a recent flare of AU, 26
(25%) had chronic uveitis. Among the 28 patients with
symptomatic uveitis at baseline, 10 (36%) had a chronic uveitis
(table 1).
AU flare rates during the year prior to enrolment
During the 12 months before and including the baseline visit, 87
patients had experienced 1 to 2 flares of AU and 19 patients had
experienced 3 or more episodes of AU. The total number of AU
flares in the year before and/or at baseline was 187.5.
Accordingly, the AU flare rates per 100 PYs were 15 flares/
100 PYs in all 1250 patients, 68.4 flares/100 PYs in the 274
patients with a history of uveitis and 176.9 flares/100 PYs in the
106 patients with a recent history of AU. The 28 patients with
symptomatic AU at baseline had experienced 54 AU flares in the
past year resulting in a rate of 192.9 flares/100 PYs. A total of
55.5 AU flares within the 1 year before adalimumab treatment
was documented among the 43 patients diagnosed with chronic
uveitis, for an AU flare rate in this group of 129.1 flares/100 PYs
(table 2).
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Among all 1250 patients in this study, the mean/median
adalimumab exposure was 106/86 days. Overall, 115 of 1250
(9.2%) patients prematurely discontinued from the study. No
patient discontinued adalimumab because of an AU episode.
The mean/median duration of adalimumab treatment was 129/
140 days in patients who had at least one AU flare in the 1 year
before enrolment and who were observed up to week 20 by
protocol.
Reduction of AU flare rates during adalimumab treatment
During 363 PYs of adalimumab treatment, 27 flares of AU were
documented in 25 out of 1250 (2%) patients. Overall,
adalimumab treatment led to clinically relevant reduction in
the incidence of AU flares. The rate of uveitis flares dropped by
51% in all 1250 patients with AS, by 58% in the 274 patients
with a history of AU, by 68% in those 106 patients with a recent
history of AU, by 50% in the 28 patients with symptomatic AU
at baseline and by 45% in the 43 patients with a history of
chronic uveitis (table 2).
Compared with the control period, the incidence of AU flares
in the complete study population was decreased for 7.3% (91/
1250) of patients, unchanged for 91.0% (1138/1250) of patients
and increased for 1.7% (21/1250) of patients.
A total of 25 AU flares were documented in 23 of 274 patients
with a history of AU; 21 AU flares occurred in 19 of 106 patients
with a recent history of AU. Of the 19 patients who had
reported at least 3 AU flares in the past year, 11 (58%) had no
relapse of AU during adalimumab treatment. Of 87 patients
who had experienced 1 to 2 AU flares in the past year, 76 (87%)
had no AU flares during adalimumab treatment. Among the 28
patients with symptomatic AU at baseline, 19 (68%) experi-
enced no AU flares during adalimumab treatment; 10 AU flares
were reported in the other 9 patients.
Table 1 Demographic and disease characteristics at baseline of patients with ankylosing spondylitis (AS)
and a history of anterior uveitis (AU)
All patients
(n=1250)
History of AU*
(n=274)
Recent history of
AU{ (n=106)
Symptomatic AU at
baseline (n=28)
Chronic AU{
(n=43)
Chronic uveitis, % 3 16 25 36 100
Male, % 71 70 74 82 72
Age, years, mean (SD) 43.6 (11.4) 45.6 (10.6) 44.0 (10.0) 46.1 (13.0) 44.4 (9.9)
AS duration, years, mean (SD) 11.0 (9.8) 14.8 (10.6) 13.4 (9.3) 14.8 (8.4) 15.1 (9.2)
Advanced AS1, % 27 31 31 41 26
Time since onset of uveitis,
years, mean (SD)
NA 9.9 (8.9) 6.6 (8.8) 7.4 (8.4) 9.4 (7.9)
HLA-B27 positive, % 82 91 89 82 90
BASDAI, mean (SD) 6.3 (1.4) 6.3 (1.4) 6.5 (1.4) 6.2 (1.7) 6.6 (1.5)
BASFI, mean (SD) 5.4 (2.2) 5.2 (2.3) 5.0 (2.5) 5.0 (2.8) 5.2 (2.5)
CRP, mg/dl, mean (SD) 2.0 (2.4) 2.4 (2.8) 2.8 (3.6) 4.1 (4.9) 2.6 (3.0)
Treatment with DMARDs, % 26 28 19 32 26
Treatment with
sulfasalazine, %
12 13 9 25 12
Oral NSAIDs, % 74 79 78 71 84
Oral glucocorticoids, % 14 13 9 14 16
Previous etanercept and/or
infliximab treatment, %
26 23 26 29 35
*History of AU, history of at least one AU flare anytime.
{Recent history of AU, history of at least one AU flare in the past year.
{Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to
the Standardization of Uveitis Nomenclature Working Group.
6
1Advanced AS, radiographically involvement of at least 50% of the spine in .2 segments.
28
BASDAI, Bath AS Disease Activity Index; BASFI, Bath AS Functional Index; CRP, C-reactive protein; DMARDs, disease-modifying
antirheumatic drugs; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs.
Table 2 Anterior uveitis flare rates per 100 patient years before and during adalimumab therapy
Patient groups by
history of AU
AU flare rate before
adalimumab treatment
(flares/100 PYs)
AU flare rate during
adalimumab treatment
(flares/100 PYs)
Reduction in AU flare
rate during
adalimumab treatment
(%) p Value*
All patients
(n=1250)
15 7.4 251 ,0.001
History of AU{
(n=274)
68.4 28.9 258 ,0.001
Recent history of
AU{ (n=106)
176.9 56 268 ,0.001
Symptomatic AU at
baseline (n=28)
192.9 96.2 250 0.001
Previous chronic
uveitis1 (n=43)
129.1 71.4 245 0.002
*Wilcoxon signed rank test.
{History of AU, history of at least one AU flare anytime. {Recent history of AU, history at least one AU flare in the past year.
1Chronic uveitis refers to persistent AU flares of at least 3-month duration and with relapse within less than 3 months according to
the Standardization of Uveitis Nomenclature Working Group.
6
AU, anterior uveitis; PYs, patient years.
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flare during adalimumab treatment was greater in patients with
a history of chronic uveitis (21%, 9/43) than in patients with a
history of acute AU (6%, 14/231). Each of the nine patients with
chronic uveitis and with an AU flare during adalimumab
treatment had experienced uveitis flares within the year before
study enrolment.
Among all patients (n=1250), 2 developed new-onset AU. In
one patient, a mild AU flare occurred 4 days after the first
adalimumab injection and ceased after 11 days topical non-
steroidal treatment. Simultaneously with the remission of
uveitis, the patient responded well to adalimumab, as indicated
by a decrease in BASDAI from 6.3 at baseline to 1.1 at week 2. In
the other patient, a moderate flare of AU occurred 90 days after
initiation of adalimumab therapy. The AU flare in this patient
was associated with a deterioration of AS activity, as suggested
by an increase in BASDAI from 2.1 at week 6 to 4.7 at week 12
and by an increase of CRP concentration from 0.2 mg/dl at
week 6 to 1.2 mg/dl at week 12.
The majority of AU flares that occurred during adalimumab
treatment were reported as mild (67%) or moderate (29%); only
oneflare was considered severebythe treatingdoctor. All patients
recovered from AU after topical anti-inflammatory treatment
except for two patients with ongoing AU at the last observation.
Inoneofthese two patients,theAUflarehadstarted1 weekafter
the last adalimumab injection; in the other patient, the onset of
the AU flare was reported 2 months before the last observation.
The time from first injection of adalimumab until onset of AU
flares varied between 4 and 113 days, with a median interval of
72 days.Themediandurationofthe25AUflareepisodesthathad
a documented date of resolution was 22 days.
ASAS and BASDAI responses
The response of AS signs and symptoms to adalimumab was
similarinallpatientsandinpatientswithahistoryofAU(table3).
At week 12, 46% of the 25 patients who had an AU flare
during adalimumab treatment achieved an ASAS40 response
compared with 54% of the 1225 patients who had no AU flare
during adalimumab treatment. The BASDAI 50 response rates
were 56% of 25 patients who had an AU flare during
adalimumab treatment and 57% of 1225 patients who had no
AU flare during adalimumab treatment. Of the 25 patients who
experienced an AU flare during adalimumab treatment, 7 (28%)
were either insufficient responders with respect to their AS
disease during the entire adalimumab treatment period, as
indicated by a change from baseline in BASDAI ,20%, or had a
relapse of AS activity before the AU flare, indicated by at least a
50% increase in the BASDAI compared with the BASDAI score
at the preceding study visit (data not shown). In three patients,
the AU flare occurred during the 70-day follow-up period;
therefore, no information on AS disease activity was available.
DISCUSSION
Our results suggest at least a 50% reduction in the AU flare rate
during adalimumab treatment of patients with active AS. The
results of this study are somewhat limited by the open-label,
uncontrolled study design but are strengthened by the large
number (.1000) of patients cared for in 211 centres in 15
European countries. Of the 1250 enrolled patients with AS, 274
had a history of AU. The AU flare rate of 15/100 PYs in all 1250
patients with AS before adalimumab treatment is similar to the
AU flare rate of 15.6/100 PYs reported by Braun and colleagues
in placebo-treated patients with AS from three pooled clinical
trials of etanercept or infliximab for AS (the range among the
three placebo groups varied from 0 to 37.2/100 PYs).
17
Treatment with adalimumab decreased the rate of AU flares
by 51% for all 1250 patients with AS to an AU flare rate of 7.4/
100 PYs. By comparison, Braun and colleagues
17 reported a
pooled AU flare rate of 3.4/100 PYs for all infliximab-treated
patients (range from 2.2 to 18.9/100 PYs in the three infliximab
studies) and a pooled AU flare rate of 7.9/100 PYs for
etanercept-treated patients (range from 0 to 9.6/100 PYs in
four etanercept studies). Information about the AU flare rates
before enrolment in these clinical studies of etanercept and
infliximab was not collected.
For the 274 patients in this study with a history of AU, the
rate of AU flares decreased by 58%, from 68.4/100 PYs to 28.9/
100 PYs during adalimumab treatment. This rate is comparable
to the rate of 21.4/100 PYs in a retrospective study of 46 TNF
antagonist-treated patients with AS or with SpA.
18 The
majority of AU flares during the study were reported for those
106 patients who had a recent history of AU (ie, at least 1 flare
within the past year). Nevertheless, in this subset of patients at
high risk for relapse of AU, the rate of AU flares was reduced by
68% during adalimumab therapy. Also, in patients with a
history of chronic uveitis, a reduction of AU flares during the
study was observed. Most of the AU flares that occurred during
adalimumab treatment were considered mild and subsided after
3 weeks in half of the patients in whom the duration of the AU
flare was known.
Table 3 Adalimumab effectiveness at week 12 in all patients and in patients with a history of anterior uveitis
(observed values)
All patients
(n=1250)
History of AU*
(n=274)
Recent history of
AU{ (n=106)
Symptomatic AU at
baseline (n=28)
Chronic AU{
(n=43)
ASAS40, % 53.7 54.5 55.1 56.0 52.4
BASDAI 50, % 57.2 60.7 61.8 66.7 59.5
ASAS partial
remission, %
27.7 32.5 32.7 40.0 33.3
CRP, mg/dl, mean
(SD)
0.8 (1.4) 1.0 (1.8) 1.2 (2.2) 1.6 (2.6) 0.9 (0.9)
CRP absolute change,
mean (SD)
21.4 (2.5) 21.9 (3.3) 22.3 (4.5) 23.8 (5.5) 22.6 (3.2)
*History of AU, history of at least one AU flare anytime.
{Recent history of AU, history of at least one AU flare in the past year. {Chronic uveitis refers to persistent AU flares of at least 3-
month duration and with relapse within less than 3 months according to the Standardization of Uveitis Nomenclature Working
Group.
6
ASAS, Assessments in Spondyloarthritis International Society criteria for response, partial remission (value of ,2 on a 0–10-point
scale in each of the four ASAS20 domains); AU, anterior uveitis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP,
C-reactive protein.
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in patients with a history of AU was comparable to the response
of all patients in the study. The comparison of adalimumab
effectiveness in patients with or without an AU flare during
treatment is limited because of the large difference in the
number of patients in the 2 groups (25 who had an AU flare vs
1225 who did not) and because of the uncontrolled study
design. However, an insufficient response or loss of response to
adalimumab as measured by AS disease activity was documen-
ted in more than 25% of patients at the time of the AU flares.
Nevertheless, most AU flares occurred in patients with a good
overall clinical response to adalimumab, suggesting that vigilant
monitoring for AU flares is necessary in patients with AS whose
disease activity is low.
Two male patients developed an episode of new-onset
unilateral AU. New-onset AU has been reported in adult and
paediatric patients treated with etanercept
19–21 33 and rarely in
patients treated with infliximab.
23 33 34 The underlying rheu-
matic disorders in patients with new-onset AU were often
diseases that are not commonly associated with AU, such as
rheumatoid arthritis.
24 Atypical bilateral AU flares were
reported in six patients with AS during anti-TNF therapy (five
patients with etanercept treatment, one patient with infliximab
treatment).
23 35 Because AU is frequently comorbid with AS, it is
difficult to determine whether the underlying AS or the anti-
TNF treatment has caused the new-onset AU. In one of the
patients in the study, the first episode of AU occurred 4 days
after the first adalimumab injection. Although a temporal
relationship between adalimumab injection and the AU flare is
apparent, this patient was in a state of high AS disease activity
at the time of the flare. The same consideration is likely for the
second patient who developed an AS flare 5 days before the first
AU flare. On the other hand, the correlation between AS disease
activity and the incidence of AU flares is generally considered to
be low.
2
During adalimumab treatment, the rate of AU flares was
reduced by 51% in all patients, by 58% in patients with a
history of AU, by 68% in patients with a recent history of AU,
by 50% in patients with symptomatic AU at baseline and by
45% in patients with chronic uveitis. Most AU flares that
occurred during adalimumab treatment were mild, and only
two patients had new-onset AU.
CONCLUSIONS
Adalimumab effectively reduces the rate of AU flares in patients
with active AS, including patients with recently symptomatic
AU and patients with chronic uveitis.
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